Leo Wealth LLC Makes New Investment in Sanofi $SNY

Leo Wealth LLC purchased a new position in Sanofi (NASDAQ:SNY) during the third quarter, HoldingsChannel reports. The firm purchased 25,063 shares of the company’s stock, valued at approximately $1,033,000.

Several other institutional investors also recently added to or reduced their stakes in the stock. Bank of America Corp DE lifted its holdings in Sanofi by 11.0% during the 1st quarter. Bank of America Corp DE now owns 9,484,350 shares of the company’s stock valued at $456,956,000 after buying an additional 940,342 shares in the last quarter. Mondrian Investment Partners LTD boosted its position in Sanofi by 2.3% in the 3rd quarter. Mondrian Investment Partners LTD now owns 5,652,139 shares of the company’s stock valued at $233,038,000 after buying an additional 129,575 shares during the period. Royal Bank of Canada grew its stake in Sanofi by 17.5% in the 1st quarter. Royal Bank of Canada now owns 3,155,080 shares of the company’s stock worth $152,011,000 after acquiring an additional 470,882 shares in the last quarter. Regal Partners Ltd grew its stake in Sanofi by 33.2% in the 1st quarter. Regal Partners Ltd now owns 2,545,432 shares of the company’s stock worth $122,639,000 after acquiring an additional 633,782 shares in the last quarter. Finally, Manning & Napier Advisors LLC increased its position in shares of Sanofi by 728,134.8% during the first quarter. Manning & Napier Advisors LLC now owns 1,194,305 shares of the company’s stock worth $57,542,000 after acquiring an additional 1,194,141 shares during the period. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Sanofi Stock Up 0.5%

Shares of Sanofi stock opened at $41.79 on Tuesday. The company has a debt-to-equity ratio of 0.21, a current ratio of 0.99 and a quick ratio of 0.64. The stock has a market cap of $101.32 billion, a price-to-earnings ratio of 21.88, a PEG ratio of 1.28 and a beta of 0.33. The firm’s 50-day moving average is $42.38 and its two-hundred day moving average is $44.46. Sanofi has a 1 year low of $39.07 and a 1 year high of $52.68.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, July 30th. The company reported $2.41 EPS for the quarter. Sanofi had a net margin of 8.66% and a return on equity of 14.19%. The business had revenue of $13.36 billion during the quarter. During the same quarter in the prior year, the firm posted $3.24 EPS. The company’s revenue for the quarter was up 16.0% compared to the same quarter last year. As a group, research analysts expect that Sanofi will post 5.00 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on SNY. Jefferies Financial Group reaffirmed a “buy” rating on shares of Sanofi in a research note on Thursday, October 1st. HSBC reissued a “buy” rating on shares of Sanofi in a research note on Thursday, September 10th. UBS Group restated a “neutral” rating on shares of Sanofi in a report on Thursday, September 17th. Wolfe Research assumed coverage on Sanofi in a research report on Friday, October 9th. They set a “peer perform” rating for the company. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Sanofi in a research report on Tuesday, September 29th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $49.50.

About Sanofi

Sanofi is a France-based global healthcare company that researches, develops, manufactures and markets prescription medicines and vaccines. Its operations focus primarily on specialty medicines, immunology, rare diseases, neurology, oncology and treatments for rare blood disorders, as well as established pharmaceutical products.

The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron; vaccines for influenza, polio, meningitis and other infectious diseases; and treatments for conditions including multiple sclerosis, hemophilia and certain rare diseases.